The study by the Data Collection on Adverse Effects of Anti-HIV Drugs (DAD) Study Group investigated the association between exposure to protease inhibitors and nonnucleoside reverse-transcriptase inhibitors and the risk of myocardial infarction in patients infected with human immunodeficiency virus (HIV). The analysis included 23,437 patients followed for a total of 94,469 person-years. The results showed that increased exposure to protease inhibitors was associated with an increased risk of myocardial infarction, with the relative rate per year of exposure being 1.16 (95% CI, 1.10 to 1.23). In contrast, exposure to nonnucleoside reverse-transcriptase inhibitors was not independently associated with an increased risk of myocardial infarction. The increased risk associated with protease inhibitors was partly explained by dyslipidemia, but the exact mechanism remains unclear. The study concluded that the duration of exposure to combination antiretroviral therapy is significantly associated with the risk of myocardial infarction, with protease inhibitors being the primary risk factor.The study by the Data Collection on Adverse Effects of Anti-HIV Drugs (DAD) Study Group investigated the association between exposure to protease inhibitors and nonnucleoside reverse-transcriptase inhibitors and the risk of myocardial infarction in patients infected with human immunodeficiency virus (HIV). The analysis included 23,437 patients followed for a total of 94,469 person-years. The results showed that increased exposure to protease inhibitors was associated with an increased risk of myocardial infarction, with the relative rate per year of exposure being 1.16 (95% CI, 1.10 to 1.23). In contrast, exposure to nonnucleoside reverse-transcriptase inhibitors was not independently associated with an increased risk of myocardial infarction. The increased risk associated with protease inhibitors was partly explained by dyslipidemia, but the exact mechanism remains unclear. The study concluded that the duration of exposure to combination antiretroviral therapy is significantly associated with the risk of myocardial infarction, with protease inhibitors being the primary risk factor.